Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DIMESKIN 1: Long-term efficacy and safety of dimethyl fumarate in moderate to severe chronic plaque psoriasis
2017-001368-40Phase 4Completed
- Sponsor
- Almirall
- Start
- Jul 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of dimethyl fumarate in psoriasis, sponsored by Almirall. Primary endpoint: Primary efficacy: PASI75 at week 24. Started Jul 2017; status: completed.
02
Drugs
dimethyl fumarate
03
Conditions
psoriasis
Beyond the preview
Go deeper on 2017-001368-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001368-40.